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A commentary on
Brief report: Blockade of Notch signaling
in muscle stem cells causes muscular dys-
trophic phenotype and impaired muscle
regeneration
by Lin, S., Shen, H., Jin, B., Gu, Y., Chen,
Z., Cao, C. et al. (2013). Stem Cells. 31,
823–828. doi: 10.1002/stem.1319
Stem cell (SC) research holds the promise
of controlling and/or curing a variety of
diseases. SC applications include cell ther-
apy, disease modeling, and developmen-
tal biology. This commentary focuses on
an important study that examined Notch
signaling in murine satellite muscle SCs
(Lin et al., 2013). The results highlight
the possible serious side effects of NOTCH
inhibitors, a class of targeted drugs that
are being examined for treating a vari-
ety of cancers (Krop et al., 2012). Skeletal
muscles, unlikemany other tissues, possess
a unique regenerative capacity (Shi and
Garry, 2006). Many researchers believe
that this unique feature may be the key
to treating myopathies, other degenera-
tive diseases, and cancer (Jackson et al.,
2010). Much of the regenerative poten-
tial of muscle depends on a population
of SCs called satellite cells (Le Grand and
Rudnicki, 2007).
The maintenance of stemness in adult
SC is regulated by two main factors: the
“SC niche” and the stemness regulatory
pathways. Stemness regulatory pathways
Abbreviations: CTX, cardiotoxin; HGF, Hepatocyte
growth factor; NICD, NOTCH intracellular domain;
SC, Stem cell.
regulate stemness via SC genes and regu-
latory transcription factors, including the
NOTCH pathway proteins. Changes in
expression of these transcription factors
regulate the balance between self-renewal
and differentiation, vital for tissue regener-
ation. NOTCH is a crucial signaling path-
way that regulates stemness during both
embryogenesis and adulthood (Le Grand
and Rudnicki, 2007). In humans, the
NOTCH signaling pathway involves four
receptors and five ligands, is extremely
complex, and is controlled by intercon-
nected positive and negative regulators
(Fouillade et al., 2012).
To add further complexity, NOTCH
family members have been shown to
carry out different and sometimes oppos-
ing functions in the same tissue and/or
cell type (Yin et al., 2010). The role of
the Notch pathway was first identified in
satellite cells from murine muscle, which
were shown to have reduced regenera-
tive potential (Le Grand and Rudnicki,
2007). Satellite cells rely on the NOTCH
pathway for maintenance of quiescence
(Mourikis et al., 2012), which is char-
acterized by reversible mitotic arrest and
reduced metabolic activity (Le Grand and
Rudnicki, 2007; Bjornson et al., 2012).
Inactivation of the NOTCH pathway is
crucial for the process of differentiation
(Bjornson et al., 2012). To understand the
role of the Notch protein in regulating
SC quiescence and muscle regeneration,
Lin et al. (2013) developed a unique con-
ditional knock-out mouse model (Pax7-
Cre+/dnMaml1+ mutant mice) in which
Notch signaling is specifically blocked
in the satellite SC using the dominant
negative pan-Notch inhibitor, dnMaml1.
The Pax7-Cre+/dnMaml1+ mutant mice
showed myopathy manifested as muscle
damage and weakness as early as 6 months
of age and a shortened life span of about
8 months. The satellite SC pool was
totally depleted in the mutant mice due
to skewing of the balance between self-
renewal and differentiation to differen-
tiation rather than self-renewal. Further,
the progeny of myoblasts showed reduced
proliferation compared to controls. These
experiments and others post cardiotoxin
(CTX)-induced injury provided evidence
that Notch pathway blockade leads to loss
of quiescence and depletion of the satel-
lite SC pool. These results are concordant
with reports of other studies that blocked
murine Notch pathway signaling by selec-
tively inhibiting the recombining bind-
ing protein-Jj (RBP-Jj), a nuclear factor
involved in the canonical Notch signaling
pathway (Bjornson et al., 2012; Mourikis
et al., 2012).
In addition to its important role
in muscle development, regeneration
and repair, the NOTCH pathway is
dysfunctional commonly in several
developmental, vascular and cardiac dis-
eases, including leukoencephalopathy
and pulmonary arterial hypertension
(Fouillade et al., 2012; Groth and Fortini,
2012). NOTCH is also dysregulated in
a variety of human tumors, including
cancers of the breast, lung, pancreas,
colon, and brain (Groth and Fortini,
2012), and in head and neck squamous
cell cancer (HNSCC) (Stransky et al.,
2011). NOTCH gene mutations have been
found in approximately 15% of HNSCC
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(Gaykalova et al., 2014), and are usually
associated with loss-of-function (Stransky
et al., 2011), gain-of-function, or both
(Gaykalova et al., 2014). Functional stud-
ies suggest that NOTCH1 may act as
a tumor suppressor gene in HNSCC
(Pickering et al., 2013).
The Lin et al. (2013) paper is perti-
nent to the clinical application of NOTCH
inhibitors, which primarily target the
presenilin/gamma-secretase aspartyl pro-
tease cleavage that releases the NOTCH
intracellular domain (NICD) from the
membrane (Fouillade et al., 2012). Marked
toxicity affecting the gastrointestinal tract
and immune systems has been demon-
strated in clinical and preclinical trials,
but muscle side effects have not yet been
noted (Groth and Fortini, 2012). However,
in combination with satellite SC exhaus-
tion associated with aging, the side effects
of NOTCH inhibitors in older cancer
patients might be substantial (Carlson
et al., 2009). Muscle side effects were not
demonstrated in clinical trials most likely
due to early termination of most trials
to date (e.g., NCT01088763), in which
acute side effects affected rapidly prolifer-
ating cellular compartments. Further, the
role of the NOTCH pathway in regulat-
ing squamous epithelial differentiation is
consistent with reports of cutaneous dis-
orders and malignancies as side effects
of NOTCH inhibitors in an Alzheimer’s
disease clinical trial (NCT00762411) and
in Notch1 knockout mice (Nicolas et al.,
2003). These results clearly show that more
research concerning the effects and side
effects of inhibiting the NOTCH pathway
in normal and tumor cells is crucial before
targeted therapeutic approaches against
the NOTCH pathway are implemented
further. In addition, to avoid possibly
severe and life-threatening skin or muscle-
related side effects, alternative therapeutic
approaches should be examined, includ-
ing intra-tumoral administration of Notch
inhibitors in preclinical models, as sug-
gested by Pickering et al. (2013). Another
approach may be to develop alternative
small molecule inhibitors or antibodies to
inhibit specific NOTCH receptors, their
activating ligands, or other components
of the NOTCH pathway in tumor cells
(Fouillade et al., 2012). For example, Wu
et al. generated antibodies that specif-
ically target murine and human Notch
receptors; short-term administration (2–3
weeks) showed fewer and less severe side
effects compared to other Notch inhibitors
(Wu et al., 2010).
Targeted therapies against stemness
regulatory pathways like NOTCH are
promising in a variety of disorders. Owing
to the high possibility ofmuscle side effects
after long-term administration, we recom-
mend following patients by physical exam
for muscle wasting and avoiding concomi-
tant use of steroids, which can lead to
myopathies. The study by Lin and col-
leagues (2013) highlights the critical gap
in SC targeting, which is a better under-
standing of SCs and their complex reg-
ulatory pathways. A detailed understand-
ing of regulatory mechanisms in SCs is
essential before we can attempt to manip-
ulate them in beneficial ways to eradicate
disorders of regeneration like muscular
dystrophy, and SC-driven resistance to
cancer therapies, while avoiding dysregu-
lation of normal SC processes and cellular
proliferation.
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